From the NIH Office of Translational Research:
IGNITE Online Q&A Webinar, Wednesday, April 19, 2017, 3:30 PM EST (Click Here to Join Webinar)
The NINDS IGNITE (Innovation Grants to Nurture Initial Translational Efforts) program is a multi-component suite of funding opportunities that is meant to facilitate the discovery and development of early-stage therapeutic biotechnology products. The following three funding opportunities have upcoming receipt dates in June 2017:
- PAR-15-070: Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33), next receipt date is June 16
- PAR-15-071: Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33), next receipt date is June 16
- RFA-NS-16-013: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33), next receipt date is June 21
The program serves as a feeder program to the later-stage therapy development programs launched by NINDS, namely the Cooperative Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) programs. An interactive Q&A session will be held for interested applicants on Wednesday, April 19, 2017 from 3:30-4:30 PM EST. All potential IGNITE applicants are encouraged to participate. Investigators can find information about these funding opportunities at our website.
If you would like to log in for this meeting, please RSVP to email@example.com. You are encouraged to submit questions before the meeting when you RSVP. While you will listen to the meeting by phone, all questions will need to be submitted online. If you are calling from out of the country, please see the attached document to find the phone number to dial.
Read the full article at: https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research/Funding-Programs-Researchers/IGNITE